Related Experiment Videos
[Salmonella enteritidis abdominal aortic aneurysm in an HIV-infected patient]
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
The microbiome in head and neck squamous cell carcinoma: Biological drivers, therapeutic interactions, and emerging clinical applications.
Critical reviews in oncology/hematology·2026
Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.
Presse medicale (Paris, France : 1983)·2026
Artificial intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.
Presse medicale (Paris, France : 1983)·2026
AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.
Presse medicale (Paris, France : 1983)·2026
Artificial Intelligence in medical research and publishing: Progress, risks, and future perspectives.
Presse medicale (Paris, France : 1983)·2026
Ethical, legal, and regulatory challenges in AI-based healthcare tools.
Presse medicale (Paris, France : 1983)·2026
Beyond one-size-fits-all: Personalising health communication to drive real behaviour change.
Presse medicale (Paris, France : 1983)·2026
High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C.
Journal of human immunity·2026
Immunosenescence and immune-organ axis dysfunction: Potential of algal bioactives and nutritional interventions for healthy ageing.
International reviews of immunology·2026
Brief Communication: LSD1 Inhibition Enhances Susceptibility of Primary AML Cells for NK Cell-Mediated Killing.
Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Somatic Hypermutations Enhance Neutralization Breadth of IGHV3-53/3-66 Public Antibodies Against SARS-CoV-2 Variants.
Immunity, inflammation and disease·2026